Everolimus
Gastrin-Producing Neuroendocrine Tumor
Explore 2 assets in Gastrin-Producing Neuroendocrine Tumor →Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Emory University
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02273752CT.gov Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer | — | Terminated | — | — | — |
NCT02031536CT.gov Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery | — | Terminated | — | — | — |
NCT01204476CT.gov Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma | — | Completed | — | — | — |
NCT00655655CT.gov Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Gastrin-Producing Neuroendocrine Tumor
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Everolimus (this asset) | Emory University | P2 | B · 60 |
| Pazopanib | National Cancer Institute (NCI) | P2 | B |
| Gefitinib | National Cancer Institute (NCI) | P2 | B |
| Sorafenib | National Cancer Institute (NCI) | P2 | B |
| Regorafenib | University of Southern California | P2 | B |
| Capecitabine | ECOG-ACRIN Cancer Research Group | P2 | B |
| Pantoprazole | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | P2 | B |
| Omeprazole | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | P2 | B |
| Romidepsin | National Cancer Institute (NCI) | P2 | CCC |
+8 more in the Gastrin-Producing Neuroendocrine Tumor cohort
Other indications for Everolimus
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Tuberous Sclerosis | — | P3 | BBB · 76 |
| Hormone Receptor-Positive Breast Cancer | — | P4 | BBB · 75 |
| Hodgkins Lymphoma | — | P2 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Everolimus in Gastrin-Producing Neuroendocrine Tumor. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/everolimus-gastrin-producing-neuroendocrine-tumor
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →